electroCore, Inc.
ECOR Healthcare Medical Devices
electroCore, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 27.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.0%, EPS grew 25.0% and free cash flow fell 443.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow ECOR
electroCore, Inc. (ECOR) EV/Sales
As of 16 October 2026, electroCore, Inc. (ECOR) trades at a EV/Sales of 1.9×. Over the past ten years it has ranged from −5.2× (March 2020) to 452× (September 2018); the current reading is higher than 46% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.0× | (76.24%) |
| FY2024 | 4.4× | 203.84% |
| FY2023 | 1.4× | 667.31% |
| FY2022 | 0.2× | 72.42% |
| FY2021 | 0.1× | (99.06%) |
| FY2020 | 11.5× | 11.71% |
| FY2019 | 10.3× | (91.37%) |
| FY2018 | 120× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.1× | 40.62% |
| Mar 2026 | 1.5× | 43.47% |
| Dec 2025 | 1.0× | (12.26%) |
| Sep 2025 | 1.2× | (12.02%) |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OM Outset Medical, Inc. compare | 0.2× |
| LUNG Pulmonx Corporation compare | 0.7× |
| ZOMDF Zomedica Corp. compare | 0.9× |
| LNSR LENSAR, Inc. compare | 1.1× |
| ECOR electroCore, Inc. | 1.9× |
| APYX Apyx Medical Corporation compare | 2.2× |
| HYPR Hyperfine, Inc. compare | 2.6× |
| LUCD Lucid Diagnostics Inc. compare | 14.3× |
| SERA Sera Prognostics, Inc. compare | 822× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)